Patient privacy focus of Amgen suit

Jan 09, 2008

Two former employees with the California biotech company Amgen Inc. allege the company persuaded sales people to access patient records to boost sales.

The employees allege Amgen officials persuaded them to access patient records and sometimes pose of medical office personnel to influence the prescription of the arthritis and psoriasis drug Enbrel, the Los Angeles Times reported Wednesday.

Federal law prohibits unauthorized access to patient's medical information. Drug companies are also prohibited from marketing off-label uses, though doctors may prescribe drugs for any reason.

A former FDA lawyer said off-label marketing "is if you have a drug for colon cancer that you promote for brain cancer" while another advocate said Amgen violated FDA regulations by persuading patients to seek the Enbrel for milder forms of the diseases it was approved treat.

Copyright 2008 by United Press International

Explore further: Cardinal Health paying $26.8 million in FTC settlement

Related Stories

FDA recommends lower doses of anemia drugs

Jun 24, 2011

(AP) -- Food and Drug Administration officials say doctors should use lower doses of anemia drugs when treating patients with failing kidneys due to the increased risk of stroke, blood clots and death.

Amgen outlines growth plan, rules out break-up

Oct 28, 2014

Biotechnology company Amgen, facing pressure from activist investor Daniel Loeb, Tuesday unveiled plans to implement deeper job cuts, lift shareholder payouts and increase revenues to more than $20 billion in 2015.

Amgen posts higher 2Q sales, profit to beat views

Jul 27, 2012

(AP) — Amgen Inc.'s second-quarter net income rose 8 percent as the world's largest biotech company benefited from higher sales for its top-selling drugs and a gain from selling its share of an experimental medicine.

The past, present and future of cancer

Mar 18, 2011

Leading cancer researchers reflected on past achievements and prospects for the future of cancer treatment during a special MIT symposium on Wednesday titled “Conquering Cancer through the Convergence of Science and ...

Recommended for you

Cardinal Health paying $26.8 million in FTC settlement

8 hours ago

Cardinal Health will pay $26.8 million as part of a settlement with the Federal Trade Commission over charges it monopolized the sale in 25 markets of diagnostic drugs known as low-energy radiopharmaceuticals.

Selecting the right tool for the job

Apr 14, 2015

Randomized clinical trials of new drugs have long been considered the "gold standard" in determining safety and efficacy before drugs, biologics, vaccines or devices are introduced to the general public. However, in the case ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.